Actelion Ltd - Product Pipeline Review - 2016

Published: Mar, 2016 | Pages: 74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Actelion Ltd - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Actelion Ltd - Product Pipeline Review - 2016', provides an overview of the Actelion Ltd's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Actelion Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Actelion Ltd
- The report provides overview of Actelion Ltd including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Actelion Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Actelion Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to Buy

- Evaluate Actelion Ltd's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Actelion Ltd
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Actelion Ltd's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Actelion Ltd Snapshot 7
Actelion Ltd Overview 7
Key Information 7
Key Facts 7
Actelion Ltd - Research and Development Overview 8
Key Therapeutic Areas 8
Actelion Ltd - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
Actelion Ltd - Pipeline Products Glance 17
Actelion Ltd - Late Stage Pipeline Products 17
Pre-Registration Products/Combination Treatment Modalities 17
Phase III Products/Combination Treatment Modalities 18
Actelion Ltd - Clinical Stage Pipeline Products 19
Phase II Products/Combination Treatment Modalities 19
Phase I Products/Combination Treatment Modalities 20
Actelion Ltd - Early Stage Pipeline Products 21
Preclinical Products/Combination Treatment Modalities 21
Discovery Products/Combination Treatment Modalities 22
Actelion Ltd - Drug Profiles 23
mechlorethamine hydrochloride 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
selexipag 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
cadazolid 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
macitentan 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ponesimod 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
miglustat 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
clazosentan 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecule to Antagonize Endothelin Receptor A and Endothelin Receptor B for Essential Hypertension 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Cenerimod 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
AC-082 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ACT-451840 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ACT-541468 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
lucerastat 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecule 2 for Neurological Disorders 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecule for Cardiovascular Disorders 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AC-080 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecule to Antagonize Orexin 2 Receptor for Sleep Disorders 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecule to Inhibit DNA Gyrase and Topoisomerase IV for Bacterial Infection 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecules for Hypertension 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecules to Antagonize Endothelin A Receptor for Hypertension 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecules to Inhibit DNA Ligase for Staphylococcal Infections 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Small Molecule for Cancer 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Actelion Ltd - Pipeline Analysis 51
Actelion Ltd - Pipeline Products by Target 51
Actelion Ltd - Pipeline Products by Route of Administration 53
Actelion Ltd - Pipeline Products by Molecule Type 54
Actelion Ltd - Pipeline Products by Mechanism of Action 55
Actelion Ltd - Recent Pipeline Updates 56
Actelion Ltd - Dormant Projects 65
Actelion Ltd - Discontinued Pipeline Products 66
Discontinued Pipeline Product Profiles 66
almorexant 66
selexipag 66
Actelion Ltd - Company Statement 67
Actelion Ltd - Locations And Subsidiaries 69
Head Office 69
Other Locations & Subsidiaries 69
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 73
Disclaimer 74

List of Tables

Actelion Ltd, Key Information 7
Actelion Ltd, Key Facts 7
Actelion Ltd - Pipeline by Indication, 2016 9
Actelion Ltd - Pipeline by Stage of Development, 2016 11
Actelion Ltd - Monotherapy Products in Pipeline, 2016 12
Actelion Ltd - Partnered Products in Pipeline, 2016 13
Actelion Ltd - Partnered Products/ Combination Treatment Modalities, 2016 14
Actelion Ltd - Out-Licensed Products in Pipeline, 2016 15
Actelion Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016 16
Actelion Ltd - Pre-Registration, 2016 17
Actelion Ltd - Phase III, 2016 18
Actelion Ltd - Phase II, 2016 19
Actelion Ltd - Phase I, 2016 20
Actelion Ltd - Preclinical, 2016 21
Actelion Ltd - Discovery, 2016 22
Actelion Ltd - Pipeline by Target, 2016 52
Actelion Ltd - Pipeline by Route of Administration, 2016 53
Actelion Ltd - Pipeline by Molecule Type, 2016 54
Actelion Ltd - Pipeline Products by Mechanism of Action, 2016 55
Actelion Ltd - Recent Pipeline Updates, 2016 56
Actelion Ltd - Dormant Developmental Projects,2016 65
Actelion Ltd - Discontinued Pipeline Products, 2016 66
Actelion Ltd, Subsidiaries 69